MIAMI, Jan. 07, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 ...
The Situation: President Trump signed an executive order ("EO") titled "Strengthening American Leadership in Digital Financial Technology" that signals a radical shift in the federal government's ...
The Staff Advisory Board enthusiastically invites you to attend the Spring Forum with Chancellor Larive on Thursday, April 24, 2025. The purpose of the SAB-supported forums is to provide staff with an ...
SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for ...
Issued on March 31, 2022, SAB 121 required public companies holding crypto on behalf of their customers to record customer-held crypto assets on their balance sheets as both an asset and a ...
SAB Biotherapeutics ( (SABS)) has provided an update. On December 29, 2025, SAB Biotherapeutics, Inc. entered into a new sales agreement with UBS Securities LLC to establish an at-the-market equity ...
NEW HOPE, Pa., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to ...
Rita Jain, M.D., joins Board as an Independent Director MIAMI, Jan. 07, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results